Marvel Biosciences Advances Closer to Human Trials after the Successful Completion of a Second Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies

 CALGARY, Alberta – (October 25, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study in dogs for its product MB-204, further validating the Company’s lead drug candidate low toxicity characteristic.   "We have now completed and further validated MB-204’s safety profile through this...

Marvel Biosciences Successfully Completes Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies

CALGARY, Alberta – (October 17, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study for its product MB-204, validating its low toxicity.   MB-204 is the Company’s lead compound and is a novel fluorinated form of Istradefylline (FDA approved anti-Parkinson’s disease drug) and is a blood...

Marvel Biosciences Highlights Recent Research on the Serotonin Theory of Depression

CALGARY, Alberta – (October 3, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) highlights recent a meta-analysis which re-evaluated the strength of the link between serotonin levels and depression.   According to the study published in Nature Molecular Psychiatry on July 20, 2022 1, despite the influence of the serotonin theory of depression, there was no...

Marvel Biosciences Announces Stock Option Grants

Calgary, Alberta, Canada, September 26, 2022 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today announced that its board of directors has approved the grant of incentive stock options (the "Options") to certain directors and officers to acquire an aggregate of 1,425,000 common shares in the capital...

Marvel Biosciences Highlights Recent Research on Link Between NASH and Alzheimer’s Disease

CALGARY, Alberta – (August 31, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) highlights recent research indicating a link between non-alcoholic steatohepatitis (NASH) and Alzheimer’s Disease (AD), two programs its lead asset, MB-204 are targeting.   A five-year longitudinal study in Sweden tracked subjects with and without NASH over the age of 65, and those with...

Marvel Biosciences Corp. Closes Second Tranch of Private Placement

Calgary, Alberta, Canada, August 9, 2022 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or“Marvel”), is pleased to report that, further to its news releases of June 21, 2022 and July 18, 2022, it has closed its non-brokered private placement of 7,200,000 units of the Company (the “Units”) at a price of $0.10 per...

Marvel Announces Identification of a Novel Formulation of its MB-204 Asset

CALGARY, Alberta – (July 21, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) is pleased to announce that its rapid formulation screening program with Catalent, Inc., has identified a novel formulation of its lead asset MB-204. The formulation involves producing a solid amorphous dispersion of MB-204 using a simple, FDA approved excipient that has improved drug exposures...

Marvel Biosciences Closes First Tranche of Private Placement

Calgary, Alberta, Canada, July 18, 2022 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to report that, further to its news release of June 21, 2022, it has closed the first tranche of its non-brokered private placement of 4,500,000 units of the Company (the “Units”) at a price of $0.10 per...

Marvel Biosciences Announces Non-Brokered Private Placement

Calgary, Alberta, Canada, June 21, 2022 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce a proposed non-brokered private placement of units (the “Units”) at a price of $0.10 per Unit for gross proceeds of up to $700,000 (the “Offering”). Each Unit will be comprised of one common...

Marvel Biosciences Initiates Formulation Development With Catalent

Calgary, Alberta, Canada, April 6, 2022 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that has initiated its pre-clinical oral formulation studies for its lead compound MB-204 with Catalent Inc. Catalent, one of the world’s largest contract research organizations, has begun...